HYDROXYZINE PAMOATE | A087479 | SANDOZ INC
| Petition | Type | Filed | Status | Petitioner |
|---|---|---|---|---|
Citizen Petition from Hyman, Phelps & McNamara P.C. FDA-2019-P-3903 · 4 docket documents Hyman, Phelps & McNamara P.C. filed this citizen petition requesting that the FDA designate ANDA 040014 (Lidocaine Hydrochloride Oral Solution, 2%, held by Hi-Tech Pharmaceuticals) as a new reference standard in the Orange Book to replace the currently unavailable reference standard approved under A | 505(q) | 2019-08-20 | Granted | Hyman, Phelps & McNamara P.C. |
Source: Regulations.gov. FDA citizen petitions matched by application number.
Highest NADAC/Unit
$0.0642
per ea
Lowest NADAC/Unit
$0.0642
per ea
Brand NDCs
0
Generic NDCs
2
| NDC Description | NADAC/Unit | Unit | Type | Generic NADAC | Effective |
|---|---|---|---|---|---|
| 00185067401HYDROXYZINE PAM 25 MG CAP | $0.0642 | EA | Generic | — | 2026-06-17 |
| 00185067405HYDROXYZINE PAM 25 MG CAP | $0.0642 | EA | Generic | — | 2026-06-17 |
Source: NADAC (data.medicaid.gov). Prices reflect national average acquisition costs for retail community pharmacies.
No patent or exclusivity listings for this strength.